CD274 and ovarian carcinoma: Although baseline biomarker data from our study do not allow robust conclusions, the only responding patient with ovarian cancer in Part 1 had the highest PD-L1 expression, and most responding patients with ovarian cancer in Part 2 also had PD-L1 IC ≥ 1%.